Alimera Sciences traded at $3.80 this Tuesday April 9th, increasing $0.02 or 0.53 percent since the previous trading session. Looking back, over the last four weeks, Alimera Sciences gained 0.80 percent. Over the last 12 months, its price rose by 83.57 percent. Looking ahead, we forecast Alimera Sciences to be priced at 3.69 by the end of this quarter and at 3.36 in one year, according to Trading Economics global macro models projections and analysts expectations.
Alimera Sciences, Inc. is a pharmaceutical company. The Company is engaged in commercialization and development of prescription ophthalmic pharmaceuticals. It focuses on diseases affecting the back of the eye or retina. The Company’s commercial product, ILUVIEN, is an intravitreal implant, which treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It is engaged in developing for the treatment of diabetic macular edema (DME). DME is a disease of retina that affects individuals with diabetes and can lead to severe vision loss and blindness. ILUVIEN can also be used to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). The Company commercially market ILUVIEN directly in the United States, Germany, United Kingdom, Portugal, and Ireland.